Abraxis BioScience Announces Date for 2009 Third Quarter Financial Results and Investor Conference Call
Business Wire
Oct 16, 2009
Abraxis BioScience, Inc. (NASDAQ:ABII), an integrated, global
biopharmaceutical company, today announced it will release its 2009
third quarter financial results before the market opens on Thursday,
November 5, 2009. The company also said that senior management will host
an investor conference call the same day at 8:30 a.m. PT/11:30 a.m. ET
to review the company’s financial results.
The conference call will be available to interested parties through a
live audio webcast at www.abraxisbio.com
and www.earnings.com.
The call will also be archived and accessible at both sites for six
months.
About Abraxis BioScience, Inc.
Abraxis BioScience is a fully integrated global biotechnology company
dedicated to the discovery, development and delivery of next-generation
therapeutics and core technologies that offer patients safer and more
effective treatments for cancer and other critical illnesses. The
company's portfolio includes the world's first and only protein-bound
nanoparticle chemotherapeutic compound (ABRAXANE®), which is
based on the company's proprietary tumor targeting technology known as
the nab® platform. The first FDA approved product to
use this nab platform, ABRAXANE, was launched in 2005 for the
treatment of metastatic breast cancer and is now approved in 38
countries. The company continues to expand the nab platform
through a robust clinical program and deep product pipeline. Abraxis
trades on the NASDAQ Global Market under the symbol ABII. For more
information about the company and its products, please visit www.abraxisbio.com.
(c) 2009 Business Wire, Inc., All rights reserved. All of the news releases and other content contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. Any copying or reproduction (other than for an individual user's personal reference), redistribution, reposting or other transmission or communication is expressly prohibited without prior written permission of Business Wire, Inc
